Article
Loss of Tyrosine Kinase 2 Does Not Affect the Severity of Jak2V617F-induced Murine Myeloproliferative Neoplasm.
Anticancer research - 1 Jul 2017
Yamaji Takumi, Shide Kotaro, Kameda Takuro, Sekine Masaaki, Kamiunten Ayako, Hidaka Tomonori, Kubuki Yoko, Shimoda Haruko, Abe Hiroo, Miike Tadashi, Iwakiri Hisayoshi, Tahara Yoshihiro, Sueta Mitsue, Yamamoto Shojiro, Hasuike Satoru, Nagata Kenji, Shimoda Kazuya
Abstract excerpt
BACKGROUND/AIM: In myeloproliferative neoplasms (MPN), Janus kinase 2 (JAK2) is activated by mutations including JAK2V617F (JAK2VF). It is unclear whether JAK kinases [i.e. JAK1, JAK2, JAK3, or tyrosine kinase 2 (TYK2)] other than JAK2 have cooperative actions such as enhancement or suppression of JAK2. If other kinases enhance activation, therapies that co-target them could have a therapeutic efficacy. We...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.